[ TRANSACTION RECORD ]

AbbVie Inc. Investment in ImmunoGen — 2023

VERIFIED VECTOR ID: 001559 · tx-087
M SOURCE NODE — FUNDER
AbbVie Inc.
Healthcare United States
$10,100,000,000
EQUITY
30/11/2023
Q DESTINATION NODE — RECIPIENT
ImmunoGen
Company United States
Amount (USD)
$10.1B
Flow Type
EQUITY
Transaction Date
30/11/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity AbbVie Inc.
AUM 300000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity ImmunoGen
Entity Type Company
Jurisdiction United States
Intelligence Note

AbbVie Inc. announced the acquisition of ImmunoGen for 10.1 billion dollars to strengthen its oncology portfolio with a leading antibody-drug conjugate therapy. The transaction provides AbbVie with a commercially available treatment for ovarian cancer. This deal represents a significant institutional investment in the next generation of targeted cancer medicines.

Σ
Primary Forensic Source https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen/
✓ SOURCE LINKED